FAQ

PM02734

Known as: Depsipeptide PM02734 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
02420062017

Related topics

Related topics

2 relations

Broader (2)

Irvalecelisidepsin

Related mentions per year

Related mentions per year

2006-2017
20002005201020152020
PM02734
elisidepsin
Irvalec

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II… (More)
  • table 1
  • figure 1
  • figure 4
Is this relevant?
2012
2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2012
2012
Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization.
PM02734 is a chemically synthesized depsipeptide derived from the marine kahalalides family with a broad spectrum of activity… (More)
Is this relevant?
2012
2012
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Irvalec® (elisidepsin trifluoroacetate, PM02734) is a novel marine-derived cyclic peptide belonging to the Kahaladide… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table II
Is this relevant?
2011
2011
PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
PURPOSE PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II… (More)
Is this relevant?
2009
2009
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
PM02734 (elisidepsin) is a novel marine-derived cyclic peptide belonging to the Kahalalide family of compounds currently under… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
Phase I dose-escalating study of PM02734 in a 24-hour infusion schedule every 21 days in advanced solid tumors.
2511 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro… (More)
Is this relevant?
2008
2008
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma.
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a… (More)
Is this relevant?